Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites

Matthew P. Glenn, Sung Youn Chang, Carrie Hornéy, Kasey Rivas, Kohei Yokoyama, Erin E. Pusateri, Steven Fletcher, Christopher G. Cummings, Frederick S. Buckner, Prakash R. Pendyala, Debopam Chakrabarti, Saïd M. Sebti, Michael Gelb, Wesley C. Van Voorhis, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, we report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple molecular architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compounds represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC50 <1 nM) and toxicity to cultured parasites at low concentrations (ED50 <100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.

Original languageEnglish (US)
Pages (from-to)5710-5727
Number of pages18
JournalJournal of Medicinal Chemistry
Volume49
Issue number19
DOIs
StatePublished - Sep 21 2006

Fingerprint

Farnesyltranstransferase
Growth Inhibitors
Plasmodium
Antimalarials
Malaria
Parasites
Plasmodium falciparum
Metabolism
Biological Availability
Developing Countries
Inhibitory Concentration 50
Toxicity
Mortality
Therapeutics
p21(ras) farnesyl-protein transferase
Lead
In Vitro Techniques

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. / Glenn, Matthew P.; Chang, Sung Youn; Hornéy, Carrie; Rivas, Kasey; Yokoyama, Kohei; Pusateri, Erin E.; Fletcher, Steven; Cummings, Christopher G.; Buckner, Frederick S.; Pendyala, Prakash R.; Chakrabarti, Debopam; Sebti, Saïd M.; Gelb, Michael; Van Voorhis, Wesley C.; Hamilton, Andrew.

In: Journal of Medicinal Chemistry, Vol. 49, No. 19, 21.09.2006, p. 5710-5727.

Research output: Contribution to journalArticle

Glenn, MP, Chang, SY, Hornéy, C, Rivas, K, Yokoyama, K, Pusateri, EE, Fletcher, S, Cummings, CG, Buckner, FS, Pendyala, PR, Chakrabarti, D, Sebti, SM, Gelb, M, Van Voorhis, WC & Hamilton, A 2006, 'Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites', Journal of Medicinal Chemistry, vol. 49, no. 19, pp. 5710-5727. https://doi.org/10.1021/jm060081v
Glenn, Matthew P. ; Chang, Sung Youn ; Hornéy, Carrie ; Rivas, Kasey ; Yokoyama, Kohei ; Pusateri, Erin E. ; Fletcher, Steven ; Cummings, Christopher G. ; Buckner, Frederick S. ; Pendyala, Prakash R. ; Chakrabarti, Debopam ; Sebti, Saïd M. ; Gelb, Michael ; Van Voorhis, Wesley C. ; Hamilton, Andrew. / Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. In: Journal of Medicinal Chemistry. 2006 ; Vol. 49, No. 19. pp. 5710-5727.
@article{af05d13ad819478b84e3aa9563c41009,
title = "Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites",
abstract = "Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, we report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple molecular architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compounds represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC50 <1 nM) and toxicity to cultured parasites at low concentrations (ED50 <100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.",
author = "Glenn, {Matthew P.} and Chang, {Sung Youn} and Carrie Horn{\'e}y and Kasey Rivas and Kohei Yokoyama and Pusateri, {Erin E.} and Steven Fletcher and Cummings, {Christopher G.} and Buckner, {Frederick S.} and Pendyala, {Prakash R.} and Debopam Chakrabarti and Sebti, {Sa{\"i}d M.} and Michael Gelb and {Van Voorhis}, {Wesley C.} and Andrew Hamilton",
year = "2006",
month = "9",
day = "21",
doi = "10.1021/jm060081v",
language = "English (US)",
volume = "49",
pages = "5710--5727",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites

AU - Glenn, Matthew P.

AU - Chang, Sung Youn

AU - Hornéy, Carrie

AU - Rivas, Kasey

AU - Yokoyama, Kohei

AU - Pusateri, Erin E.

AU - Fletcher, Steven

AU - Cummings, Christopher G.

AU - Buckner, Frederick S.

AU - Pendyala, Prakash R.

AU - Chakrabarti, Debopam

AU - Sebti, Saïd M.

AU - Gelb, Michael

AU - Van Voorhis, Wesley C.

AU - Hamilton, Andrew

PY - 2006/9/21

Y1 - 2006/9/21

N2 - Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, we report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple molecular architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compounds represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC50 <1 nM) and toxicity to cultured parasites at low concentrations (ED50 <100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.

AB - Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, we report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple molecular architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compounds represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC50 <1 nM) and toxicity to cultured parasites at low concentrations (ED50 <100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.

UR - http://www.scopus.com/inward/record.url?scp=33748858487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748858487&partnerID=8YFLogxK

U2 - 10.1021/jm060081v

DO - 10.1021/jm060081v

M3 - Article

VL - 49

SP - 5710

EP - 5727

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -